Dopamine

Dopamine


DOPAMINE

INTRODUCTION:

  • Dopamine belongs to family of catecholamines.
  • Major neurotransmitter in substantia nigra.
  • Generates slow IPSP in ANS.
  • Significant role in learning, goal-directed behavior, regulation of hormones & motor control.

DOPAMINE RECEPTORS:

  • Metabotropic G-protein coupled receptors

D1 – like family:

  • Includes subtypes D1 & D5.
  • Activation is coupled to Gs.
  • Activates adenylyl cylcase resulting in increased cAMP concentration.

D2 – like family:

  • Includes D2, D3 & D4.
  • Activation is coupled to Gi.
  • Inhibits adenylyl cyclase leading to decreased cAMP concentration.
  • Also open K channels & closes Ca influx.
  • Dopamine receptor with inhibitory action is D2.

Subtypes

Location

Function

D1

Putamen, nucleus accumbens i.e nigrostrial pathway

Inhibition causes extrapyrimidal disorders

D2

Striatum,substantia nigra , pituitary

Control behaviour,voluntary, prolactin release

D3

Midbrain, mucleus accumbens & hypothalamus

 

D4

Frontal cortex, medulla and midbrain i.e mesocortical pathway

 

 Anti-psychotic drugs act through DopamineD4 receptor blockade.

D5

Hypothalamus & hippocampus

 

DOPAMINERGIC PATHWAYS:

  • Mesolimbic Pathway.
  • Mesocortical Pathway.
  • Nigrostriatal Pathway:
  • Efferent fiber bundle of substantia nigra transmits dopamine to Corpus striatum.
  • Tuberoinfundibular Pathway.
  • Incertohypothalamic Pathway.
  • Medullary Periventricular.
  • Retinal.

DRUGS MODIFYING DOPAMINERGIC TRANSMISSION:

Mechanism

Drug

Effect

Use

Synthesis

L-DOPA

↑ Synthesis

Parkinson’s disease

 

2 methyl-p- tyrosine

Inhibits tyrosine hydroxylase

expts

 

Carbidopa , Benserazide

Inhibit dopa decarboxylase

Parkinsonism

Storage

Reserpine, Tetrabenzine

Disrupt storage

Tranquilizer

 

MAO inhibitors

Enhance storage

 

Release

Amphetamine, Tyramine, Mazindole

Release dopamine on receptors

Anorectic, CNS stimulant

Inactivation of uptake

Amphetamine, Cocaine,

 

CNS stimulant

 

Anorectic

 

Benztropine

Benzhexol

 

Parkinson’s disease

Inactivation of metabolism

Iproniazid, Tranylcypromine,

Nonselective MAO inhibitors

 
 

Selegiline

MAO inhibitors

Parkinson’s disease

USES:

Schizophrenia:

  • Defective dopamine neurotransmission – relative excess of central dopaminergic activity.
  • An increase in DA function in mesolimbic system and decreased function in mesocortical DA systems (D1 predominates).
  • Behavior similar to behavioral effects of psychostimulants.

Parkinson’s Disease

  • Parkinson’s sufferers have low levels of dopamine.
  • L-dopa raises DA activity.
  • People with Parkinson’s develop schizophrenic symptoms if they take too much L-dopa.
  • Treatment strategy includes –
  • Increasing dopamine levels, nerve grafting with dopamine containing cells and deep brain stimulation.
  • Bromocriptine,Ropinerole & Pramipexole are dopaminergic agonists used for parkinsonism.

 Other motor disorders:

  • Huntington’s disease
  • Tourrette’s syndrome
  • D2 Blockers – Chlorpromazine & Haloperidol.

Attention deficit hyperactivity disorder

  • Altered dopamine neurotransmission is implicated in attention deficit hyperactivity disorder (ADHD).
  • Most effective therapeutic agents for ADHD are psychostimulants.
  • Methylphenidate & Amphetamine
  • Increase both dopamine & norepinephrine levels in brain.

Addiction:

  • Psychostimulants such as Cocaine & Amphetamine.
  • By altering dopamine activity in brain.
  • Inhibits prolactin secretion by acting on D2 receptors.

Role in renal system:

  • Dopamine at 1-2 Microgram/ Kg/ min produces renal vasodilatation by acting on D1 receptors.
  • Preferred in treatment of shock with oliguric renal failure.
  • Effectiveness attributed to renal vasodilatory effect.
  • Selectively activates dopamine specific receptors in the renal and splanchnic circulation.
  • Increase renal blood flow.
  • Increases GFR.
  • Increases urinary Na excretion.
  • Effect of dopamine on kidney is blocked by Haloperidol.
  • Heart and Vasculature:
  • Causes vasoconstriction.
  • At low concentrations, circulating DA primarily stimulates vascular D1 receptors, causing vasodilation and reducing cardiac afterload.
  • Activates adrenergic receptors to further increase cardiac contractility.
  • The net result is a decrease in blood pressure and an increase in cardiac contractility.
  • Drug most useful in cardiogenic shock.
  • Anti-insulin
  • Analgesic.
  • Role in apoptosis.
  • Memory.
  • Immune.

Exam Question

  • The strategy for therapy for dopamine deficiency in the substantia nigra of individuals with Parkinson’s disease is indicated by provision of metabolites in the tyrosine pathway.
  • Neurotransmitter related to schizophrenia pathology is dopamine.
  • The efferent fiber bundle of the substantia nigra transmits dopamine to Corpus striatum.
  • Dopamine is the major neurotransmitter in substantia nigra.
  • Slow IPSP in autonomic is generated by dopamine.
  • Adrenaline, noradrenaline and dopamine act through seven pass receptor.
  • Dopamine shows positive ionotropic effect.
  • Dopamine improves renal perfusion.
  • Dopamine causes vasoconstriction. 
  • Effect of dopamine on kidney is blocked by Haloperidol.
  • Dopamine is preferred in treatment of shock because of renal vasodilatory effect.
  • Prolactin secretion will be inhibited by dopamine.
  • Bromocriptine,Ropinerole & Pramipexole are dopaminergic agonists used for parkinsonism.
  • Dopamine neurotransmitter is depleted in Parkinson’s disease
  • Drug most useful in cardiogenic shock is dopamine.
  • Dopamine is preferred over dobutamne in treatment of renal shock because of renal vasodilatory effect.
  • Anti-psychotic drugs act through Dopamine D4 receptor blockade.
  • Dopamine at 1-2 Microgram/ Kg/ min produces renal vasodilatation.
  • Dopamine receptor with inhibitory action is D2.
Don’t Forget to Solve all the previous Year Question asked on Dopamine

Leave a Reply

Discover more from New

Subscribe now to keep reading and get access to the full archive.

Continue reading

👨‍⚕️
Chat Support